25-Feb-2025 6:05 AM CST - Business Wire Edwards Lifesciences to Present at the TD Cowen 45th Annual Health Care Conference Edwards Lifesciences Corporation (NYSE: EW) today announced it will participate in the TD Cowen 45th Annual Health Care Conference on Tuesday, Mar. 4, 2025. Scott Ullem, chief financial officer, is scheduled to present at 9:50 a.m. ET. A live webcast of the presentation will be available on the Edwards Lifesciences investor relations website at http://ir.edwards.com/, with an archived version accessible later the same day. About Edwards Lifesciences Edwards Life
20-Feb-2025 9:32 AM CST - MSN Should Edwards Lifesciences Stock Remain in Your Portfolio Now? Edwards Lifesciences' EW fourth-quarter performance was backed by its most comprehensive structural heart disease portfolio. The Surgical Structural Heart business is benefiting from the strong adoption of premium surgical technologies worldwide.
11-Feb-2025 3:15 PM CST - Business Wire Edwards Lifesciences Reports Fourth Quarter Results Edwards Lifesciences (NYSE: EW) today reported financial results for the quarter and full-year ended Dec. 31, 2024. Highlights and Outlook Q4 sales grew 9% to $1.39 billion1, better than expected, with strength across all product groups Q4 TAVR sales grew 6%; constant currency2 sales grew 5% Q4 TMTT sales grew 88% to $105 million with increasing contribution to Edwards' growth Q4 EPS of $0.581; adjusted2 EPS of $0.59, driven by strong top-line performance Presen
4-Feb-2025 6:05 AM CST - Business Wire Edwards Lifesciences to Host Earnings Conference Call on February 11, 2025 Edwards Lifesciences (NYSE: EW) plans to announce its operating results for the quarter ended December 31, 2024 after the market closes on Tuesday February 11, 2025, and will host a conference call at 5:00 p.m. ET that day to discuss those results. To participate in the conference call, dial (877) 704-2848 or (201) 389-0893. The call will also be available live and archived on the Investor Relations section of the Edwards website at ir.edwards.com. About Edwar
7-Jan-2025 6:05 AM CST - Business Wire Edwards Lifesciences to Present at the 43rd Annual J.P. Morgan Healthcare Conference Edwards Lifesciences Corporation (NYSE: EW) today announced it will participate in the J.P. Morgan Healthcare Conference on Tuesday, Jan. 14, 2025. Bernard Zovighian, chief executive officer, is scheduled to present at 11:15 a.m. PT. Scott Ullem, chief financial officer, will also participate in the conference. A live webcast of the presentation will be available on the Edwards Lifesciences investor relations website at http://ir.edwards.com/, with an archived v
4-Dec-2024 5:00 AM CST - Business Wire Edwards Lifesciences Outlines Growth Strategy at Annual Investor Conference Edwards Lifesciences Corporation (NYSE: EW) will discuss the companys focused strategy for long-term sustainable growth, provide an update on its technology pipeline to serve more patients and share financial guidance today during its annual investor conference. Edwards enters 2025, its first full year as a purely structural heart company, in a strong position with major growth drivers in Transcatheter Aortic Valve Replacement (TAVR) and Transcatheter Mitral and Tric
24-Oct-2024 3:21 PM CST - Business Wire Edwards Lifesciences Reports Third Quarter Results Edwards Lifesciences (NYSE: EW) today reported financial results for the quarter ended Sept. 30, 2024. Highlights and Outlook Q3 sales from continuing operations grew 9%; constant currency1 sales grew 10% Q3 TAVR sales grew 6%; constant currency1 sales grew 7% TMTT sales grew 73%; PASCAL and EVOQUE commercial launches continue to progress well Q3 EPS of $5.13; adjusted1 EPS of $0.67 Completed sale of Critical Care in Q3, resulting in significant one-time gain Pi
23-Oct-2024 4:35 PM CST - Seeking Alpha Edwards Lifesciences Q3 2024 Earnings Preview Edwards Lifesciences (NYSE:EW) is scheduled to announce Q3 earnings results on Thursday, October 24th, after market close. The consensus EPS Estimate is $0.60 (+1.7% Y/Y) and the consensus Revenue Estimate is $1.
Latest EW Trades by Congress Members
11-APR-2024 - Mike Kelly, PA (District 16) sold between $1,001 and $15,000.
25-Feb-2025 6:05 AM CST - Business Wire Edwards Lifesciences to Present at the TD Cowen 45th Annual Health Care Conference Edwards Lifesciences Corporation (NYSE: EW) today announced it will participate in the TD Cowen 45th Annual Health Care Conference on Tuesday, Mar. 4, 2025. Scott Ullem, chief financial officer, is scheduled to present at 9:50 a.m. ET. A live webcast of the presentation will be available on the Edwards Lifesciences investor relations website at http://ir.edwards.com/, with an archived version accessible later the same day. About Edwards Lifesciences Edwards Life
20-Feb-2025 9:32 AM CST - MSN Should Edwards Lifesciences Stock Remain in Your Portfolio Now? Edwards Lifesciences' EW fourth-quarter performance was backed by its most comprehensive structural heart disease portfolio. The Surgical Structural Heart business is benefiting from the strong adoption of premium surgical technologies worldwide.
11-Feb-2025 3:15 PM CST - Business Wire Edwards Lifesciences Reports Fourth Quarter Results Edwards Lifesciences (NYSE: EW) today reported financial results for the quarter and full-year ended Dec. 31, 2024. Highlights and Outlook Q4 sales grew 9% to $1.39 billion1, better than expected, with strength across all product groups Q4 TAVR sales grew 6%; constant currency2 sales grew 5% Q4 TMTT sales grew 88% to $105 million with increasing contribution to Edwards' growth Q4 EPS of $0.581; adjusted2 EPS of $0.59, driven by strong top-line performance Presen
4-Feb-2025 6:05 AM CST - Business Wire Edwards Lifesciences to Host Earnings Conference Call on February 11, 2025 Edwards Lifesciences (NYSE: EW) plans to announce its operating results for the quarter ended December 31, 2024 after the market closes on Tuesday February 11, 2025, and will host a conference call at 5:00 p.m. ET that day to discuss those results. To participate in the conference call, dial (877) 704-2848 or (201) 389-0893. The call will also be available live and archived on the Investor Relations section of the Edwards website at ir.edwards.com. About Edwar
7-Jan-2025 6:05 AM CST - Business Wire Edwards Lifesciences to Present at the 43rd Annual J.P. Morgan Healthcare Conference Edwards Lifesciences Corporation (NYSE: EW) today announced it will participate in the J.P. Morgan Healthcare Conference on Tuesday, Jan. 14, 2025. Bernard Zovighian, chief executive officer, is scheduled to present at 11:15 a.m. PT. Scott Ullem, chief financial officer, will also participate in the conference. A live webcast of the presentation will be available on the Edwards Lifesciences investor relations website at http://ir.edwards.com/, with an archived v
4-Dec-2024 5:00 AM CST - Business Wire Edwards Lifesciences Outlines Growth Strategy at Annual Investor Conference Edwards Lifesciences Corporation (NYSE: EW) will discuss the companys focused strategy for long-term sustainable growth, provide an update on its technology pipeline to serve more patients and share financial guidance today during its annual investor conference. Edwards enters 2025, its first full year as a purely structural heart company, in a strong position with major growth drivers in Transcatheter Aortic Valve Replacement (TAVR) and Transcatheter Mitral and Tric
24-Oct-2024 3:21 PM CST - Business Wire Edwards Lifesciences Reports Third Quarter Results Edwards Lifesciences (NYSE: EW) today reported financial results for the quarter ended Sept. 30, 2024. Highlights and Outlook Q3 sales from continuing operations grew 9%; constant currency1 sales grew 10% Q3 TAVR sales grew 6%; constant currency1 sales grew 7% TMTT sales grew 73%; PASCAL and EVOQUE commercial launches continue to progress well Q3 EPS of $5.13; adjusted1 EPS of $0.67 Completed sale of Critical Care in Q3, resulting in significant one-time gain Pi
23-Oct-2024 4:35 PM CST - Seeking Alpha Edwards Lifesciences Q3 2024 Earnings Preview Edwards Lifesciences (NYSE:EW) is scheduled to announce Q3 earnings results on Thursday, October 24th, after market close. The consensus EPS Estimate is $0.60 (+1.7% Y/Y) and the consensus Revenue Estimate is $1.
